Market News

    RSS Feed

OncBioMune Signs Term Sheet to Acquire Vitel Laboratorios, S.A. de C.V.

OncBioMune Logo1

November 3, 2016 | BATON ROUGE, LA–(Marketwired – November 03, 2016) – OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that it signed a non-binding term sheet to acquire Vitel Laboratorios, S.A. de C.V. (“Vitel”), a revenue-stage  … Read More

OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax(TM) in Mexico

OncBioMune Logo1

October 19, 2016 | OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notice of Allowance from the Mexican Institute of Industrial Property for OncBioMune’s patent application number MX/a/2013/008188.  … Read More

DelMar Pharmaceuticals Presents Overview of VAL-083’s Unique Anticancer Mechanism

DelMar logo

October 17, 2016 | VANCOUVER, British Columbia, and MENLO PARK, Calif., Oct. 17, 2016 /PRNewswire/ — DelMar Pharmaceuticals (NASDAQ:DMPI) , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, is pleased to announce that the Company presented additional data regarding VAL-083’s unique anti-cancer mechanism on Saturday October 15, 2016 at  … Read More